The Mediator Complex Subunit 12 (MED-12) Gene and Uterine Fibroids: a Systematic Review.
Fibroid pathophysiology
Leiomyoma
MED-12 gene
Uterine fibroids
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
29 Jul 2023
29 Jul 2023
Historique:
received:
27
02
2023
accepted:
09
07
2023
medline:
30
7
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
aheadofprint
Résumé
Uterine leiomyomas are the most common tumor of reproductive-age women worldwide. Although benign, uterine fibroids cause significant morbidity and adversely impact the quality of life for affected women. Somatic mutations in the exon 2 of the mediator complex subunit 12 (MED-12) gene represent the most common single gene mutation associated with uterine leiomyomas. The objective of this review was to evaluate the current role of MED-12 mutation in the pathophysiology of uterine fibroids, to assess the prevalence of MED-12 mutation among different populations, and to identify the most common subtypes of MED-12 mutations found in uterine fibroids. A comprehensive search was conducted using Pubmed, Embase, Scopus, and the Web of Science. English-language publications that evaluated MED-12 mutation and uterine fibroids in humans, whether experimental or clinical, were considered. We identified 380 studies, of which 23 were included, comprising 1353 patients and 1872 fibroid tumors. Of the total number of tumors analyzed, 1045 (55.8%) harbored a MED-12 mutation. Among the 23 studies included, the frequency of MED-12 mutation varied from 31.1 to 80% in fibroid samples. The most common type of MED-12 mutation was a heterozygous missense mutation affecting codon 44 of exon 2, specifically the nucleotide 131. Studies reported that MED-12 mutation acts by increasing levels of AKT and disrupting the cyclin C-CDK8/19 kinase activity. The overall average prevalence of MED-12 mutation in uterine fibroids was found to be 55.8% across the global population, though the frequency varied greatly among different countries.
Identifiants
pubmed: 37516697
doi: 10.1007/s43032-023-01297-7
pii: 10.1007/s43032-023-01297-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Society for Reproductive Investigation.
Références
Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health. 2014. https://doi.org/10.2147/IJWH.S51083 .
Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003. https://doi.org/10.1067/mob.2003.99 .
Stewart EA. Uterine fibroids. Lancet. 2001. https://doi.org/10.1016/S0140-6736(00)03622-9 .
Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012. https://doi.org/10.1186/1472-6874-12-6 .
Eltoukhi HM, Modi MN, Weston M, Armstrong AY, Stewart EA. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014. https://doi.org/10.1016/j.ajog.2013.08.008 .
Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008. https://doi.org/10.1016/j.bpobgyn.2008.01.008 .
Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006. https://doi.org/10.1016/j.ajog.2006.02.020 .
Go VAA, Thomas MC, Singh B, Prenatt S, Sims H, Blanck JF, Segars JH. A systematic review of the psychosocial impact of fibroids before and after treatment. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.05.044 .
Kämpjärvi K, Mäkinen N, Mehine M, et al. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas. Br J Cancer. 2016. https://doi.org/10.1038/bjc.2016.130 .
Mäkinen N, Kämpjärvi K, Frizzell N, Bützow R, Vahteristo P. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer. 2017. https://doi.org/10.1186/s12943-017-0672-1 .
Mehine M, Kaasinen E, Heinonen H-R, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A. 2016. https://doi.org/10.1073/pnas.1518752113 .
Kampjarvi K, Makinen N, Kilpivaara O, et al. Somatic MED12 mutations in uterine and colorectal cancer. Br J Cancer. 2012. https://doi.org/10.1038/bjc.2012.428 .
Perot G, Croce S, Ribeiro A, et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One. 2012. https://doi.org/10.1371/journal.pone.0040015 .
Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: state of the art and perspectives. Eur J of Can. 2015. https://doi.org/10.1016/j.ejca.2015.04.023 .
Taatjes DJ. The human mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci. 2010. https://doi.org/10.1016/j.tibs.2010.02.004 .
Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013. https://doi.org/10.1056/NEJMoa1302736 .
Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA. 2015. https://doi.org/10.1001/jama.2015.3656 .
Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol. 2014. https://doi.org/10.1016/j.humpath.2013.08.005 .
Lee M, Cheon K, Chae B, et al. Analysis of MED12 mutation in multiple uterine leiomyomas in South Korean patients. Int J Med Sci. 2018. https://doi.org/10.7150/ijms.21856 .
Ko YA, Jamaluddin MFB, Adebayo M, et al. Extracellular matrix (ECM) activates β-catenin signaling in uterine fibroids. Reproduction. 2018. https://doi.org/10.1530/REP-17-0339 .
Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011. https://doi.org/10.1126/science.1208930 .
Ajabnoor GMA, Mohammed NA, Banaganapalli B, et al. Expanded somatic mutation spectrum of MED12 gene in uterine leiomyomas of Saudi Arabian women. Front Genet 2018. https://doi.org/10.3389/fgene.2018.00552 .
Ahmadi A-R, Porrahim H, Moghadasi H, Najafi N, Rakhshan A. MED12 exon 2 mutations in uterine leiomyoma’s in women patients of Tehran Province of Iran. J Pharm Sci Res. 2015;7(12):1099–102.
Di Tommaso S, Tinelli A, Malvasi A, Massari S. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma. Mol Hum Reprod. 2014. https://doi.org/10.1093/molehr/gau055 .
El Andaloussi A, Al-Hendy A, Ismail N, Boyer TG, Halder SK. Introduction of somatic mutation in MED12 induces Wnt4/β-catenin and disrupts autophagy in human uterine myometrial cell. Reprod Sci. 2020. https://doi.org/10.1007/s43032-019-00084-7 .
Fazeli E, Piltan S, Gholami M, et al. CYP24A1 expression analysis in uterine leiomyoma regarding MED12 mutation profile. Arch Gynecol Obstet. 2021. https://doi.org/10.1007/s00404-020-05825-7 .
Galindo LJ, Hernández-Beeftink T, Salas A, et al. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas. Gynecol Oncol. 2018. https://doi.org/10.1016/j.ygyno.2018.07.007 .
Halder SK, Laknaur A, Miller J, Layman LC, Diamond M, Al-Hendy A. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015. https://doi.org/10.1007/s00438-014-0938-x .
Hayden MA, Ordulu Z, Gallagher CS, et al. Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata. Cancer genetics. 2018. https://doi.org/10.1016/j.cancergen.2018.01.001 .
Jamaluddin MFB, Ko YA, Kumar M, et al. Proteomic profiling of human uterine fibroids reveals upregulation of the extracellular matrix protein periostin. Endocrinology. 2018. https://doi.org/10.1210/en.2017-03018 .
Je EM, Kim MR, Min KO, Yoo NJ, Lee SH. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer. 2012. https://doi.org/10.1002/ijc.27610 .
Mäkinen N, Heinonen H-R, Moore S, Tomlinson IPM, Van der Spuy ZM, Aaltonen LA. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011. https://doi.org/10.18632/oncotarget.370 .
Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer. 2012. https://doi.org/10.1002/ijc.27424 .
Matsubara A, Sekine S, Yoshida M, et al. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology. 2013. https://doi.org/10.1111/his.12039 .
McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One. 2012. https://doi.org/10.1371/journal.pone.0033251 .
Park MJ, Shen H, Kim NH, et al. Mediator kinase disruption in MED12-mutant uterine fibroids from Hispanic women of South Texas. J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-00863 .
Sadeghi S, Khorrami M, Amin-Beidokhti M, et al. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients. Tumour Biol. 2016. https://doi.org/10.1007/s13277-015-3943-8 .
Shahbazi S, Fatahi N, Amini-Moghaddam S. Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women. Am J Cancer Res. 2015;5(8):2441–6.
pubmed: 26396919
pmcid: 4568779
Turunen M, Spaeth JM, Keskitalo S, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep. 2014. https://doi.org/10.1016/j.celrep.2014.03.047 .
Wu J, Zou Y, Luo Y, et al. Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma. Oncol Lett. 2017. https://doi.org/10.3892/ol.2017.6120 .
Munro MG, Critchley HO, Fraser IS, FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril. 2011;2011 https://doi.org/10.1016/j.fertnstert.2011.03.079 .
Mittal P, Shin YH, Yatsenko SA, Castro CA, Surti U, Rajkovic A. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest. 2015. https://doi.org/10.1172/JCI81534 .
Bateman NW, Tarney CM, Abulez TS, et al. Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry. iScience. 2021. https://doi.org/10.1016/j.isci.2021.103665 .
George JW, Fan H, Johnson B, et al. Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Cell Rep. 2019. https://doi.org/10.1016/j.celrep.2019.11.077 .
Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013. https://doi.org/10.1055/s-0033-1348896 .
Wei JJ, Chiriboga L, Arslan AA, Melamed J, Yee H, Mittal K. Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata. Hum Reprod. 2005. https://doi.org/10.1093/humrep/dei309 .
Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in Black Americans. Fertil Steril. 2006. https://doi.org/10.1016/j.fertnstert.2006.01.052 .
Bertsch E, Qiang W, Zhang Q, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014. https://doi.org/10.1038/modpathol.2013.243 .
Mas A, Cervelló I, Fernández-Álvarez A, et al. Overexpression of the truncated form of high mobility group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation. Mol Hum Reprod. 2015. https://doi.org/10.1093/molehr/gau114 .
Lyon MF. X-chromosome inactivation. Curr Biol 1999. https://doi.org/10.1016/s0960-9822(99)80151-1 .
Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005. https://doi.org/10.1038/nrc1692 .
Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002. https://doi.org/10.1038/nrc839 .
Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001. https://doi.org/10.1038/35077225 .